Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination
M33 is a branched peptide currently under preclinical characterization for development as a new drug against Gram-negative bacteria. Here we report its antibacterial activity in conjugation or combination with levofloxacin (LVFX), a fluoroquinolone antibiotic. Antibacterial assays showed no significant differences in activity when used in conjugation, while the combination of M33 and LVFX showed improved activity against Gram-negative bacteria. Combination treatment therefore opposes antimicrobial-resistance, restoring the effect of LVFX.
Federica Ceccherini (SetLance srl), Chiara Falciani (SetLance srl), Martina Onori (SetLance srl), Silvia Scali (University of Siena), Simona Pollini (University of Siena), Gian Maria Rossolini (University of Siena, University of Florence, Florence Careggi University Hospital), Luisa Bracci (University of Siena, Siena University Hospital) and Alessandro Pini (University of Siena, Siena University Hospital)
Read more PneumoNP news
New publication: Into the killing activity of an antimicrobial peptide against antibiotic-resistant K. pneumoniae